首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   9篇
  完全免费   5篇
  眼科学   14篇
  2020年   1篇
  2019年   1篇
  2016年   1篇
  2015年   1篇
  2014年   2篇
  2012年   1篇
  2011年   2篇
  2010年   1篇
  2009年   2篇
  2008年   1篇
  2006年   1篇
排序方式: 共有14条查询结果,搜索用时 62 毫秒
1.
Avastin在眼科应用的研究进展   总被引:3,自引:0,他引:3  
Avastin是第一个被美国FDA批准的通过抑制血管生成发挥抗癌作用的新药,是现行几种抗血管生成制剂之一,可抑制血管内皮生长因子(VEGF)的生成,近年研究表明,该药在治疗眼部新生血管性以及渗出性病变中疗效显著,而且价格便宜,应用前景十分广阔。  相似文献
2.
CASE REPORT: An 11-year-old girl diagnosed with Fanconi anemia was referred to us for redness and pain in her right eye. Findings in the right eye included visual acuity of counting fingers, neovascular glaucoma, vitreous hemorrhage, optic disc neovascularization, and features of peripheral ischemic retinopathy. Findings in the left eye included peripheral retinal neovascularization and areas of retinal capillary nonperfusion. COMMENTS: Patients with Fanconi anemia may develop ocular neovascularization with subsequent severe visual loss due to vitreous hemorrhage or neovascular glaucoma. Regular ophthalmic examination, including ophthalmoscopy and fluorescein angiography in selected cases, is recommended in such patients.  相似文献
3.
周骏  刘涛 《国际眼科杂志》2016,16(11):2053-2058
新生血管是许多致盲性眼病的主要原因,例如糖尿病视网膜病变、早产儿视网膜病变、年龄相关性黄斑变性等。血管内皮生长因子( vascular endothelial growth factor, VEGF)在新生血管的形成中起着重要的作用,被认为是作用最强的血管生长因子。胎盘生长因子( placental growth factor, PlGF)是VEGF家族中的一员,可促进新生血管生成,刺激内皮细胞迁移增殖,介导免疫炎症反应,且特异性表达于病理性新生血管,但在正常血管中不表达。因此近年来PlGF逐渐受到人们关注。本文对PlGF在新生血管性眼病中的作用机制进行探讨。  相似文献
4.
5.
眼部新生血管是多种眼病引发视力障碍的重要原因.骨髓来源细胞(bone marrow-derived cells,BMC)经动员、迁移、黏附和分化等步骤参与其中,受衰老、吸烟等危险因素影响,是一个复杂的需要精确调控的过程.目前,BMC参与眼部新生血管形成的分子机制已成为研究的热点和难点,阐明其中的机制对了解眼部新生血管发生及以BMC为靶点的临床疾病治疗探索具有重要意义.  相似文献
6.
7.
新生血管形成是很多重要眼部疾病的共同病理改变,血管内皮生长因子(vascularendo-thelialgrowthfactor,VEGF)是血管生成重要的促进因子。近年来,可溶性血管内皮生长因子受体-2(solubleVEGFreceptor-2,sVEGFR-2)被证实为一种VEGF促血管生成信号转导通路的天然抑制剂。有研究表明,它与眼部新生血管的发生发展密切相关,可作为新生血管性眼病的抑制因子及其血清标志物而具有临床应用价值。本文就sVEGFR-2在抗眼部新生血管中作用的研究进展予以综述。  相似文献
8.
Artemisinin, also named qinghaosu, is a family of sesquiterpene trioxane lactone originally derived from the sweet wormwood plant (Artemisia annua), which is a traditional Chinese herb that has been universally used as anti-malarial agents for many years. Evidence has accumulated during the past few years which demonstrated the protective effects of artemisinin and its derivatives (artemisinins) in several other diseases beyond malaria, including cancers, autoimmune disorders, inflammatory diseases, viral and other parasite-related infections. Recently, this long-considered anti-malarial agent has been proved to possess anti-oxidant, anti-inflammatory, anti-apoptotic and anti-excitotoxic properties, which make it a potential treatment option for the ocular environment. In this review, we first described the overview of artemisinins, highlighting the activity of artemisinins to other diseases beyond malaria and the mechanisms of these actions. We then emphasized the main points of published results of using artemisinins in targeting ocular disorders, including uveitis, retinoblastoma, retinal neurodegenerative diseases and ocular neovascularization. To conclude, we believe that artemisinins could also be used as a promising therapeutic drug for ocular diseases, especially retinal vascular diseases in the near future.  相似文献
9.
The treatment of ocular neovascular diseases is being revolutionized by intravitreal therapies targeting vascular endothelial growth factor (VEGF). Two agents are approved for treating neovascular age-related macular degeneration and are being evaluated for other retinal conditions: the RNA aptamer pegaptanib and the monoclonal antibody antigen-binding fragment ranibizumab. Bevacizumab, a related antibody, is being used similarly, although its use is off-label. Pegaptanib selectively binds to a VEGF isoform identified as being especially pathogenic in the eye and spares other isoforms, whereas the other two agents nonselectively bind all VEGF isoforms. Because VEGF is involved in a wide variety of physiologic processes, the ocular and systemic safety of anti-VEGF agents is of paramount concern. I provide an overview of safety data for intravitreal anti-VEGF therapies, focusing primarily on randomized, controlled trials. For pegaptanib, an accumulation of data from pivotal trials and a dedicated systemic safety study have revealed no ocular or systemic safety concerns. For ranibizumab, the principal ocular adverse event detected in clinical trials was a low frequency of ocular inflammation, and systemic adverse events included a slightly elevated risk of nonocular hemorrhage and stroke. Safety data from properly designed randomized controlled trials for bevacizumab are not available.  相似文献
10.
薛文文  邹海东 《国际眼科杂志》2011,11(12):2138-2140
眼部新生血管性疾病严重危害视力,目前的动物实验已证明内皮抑素(endostatin,ES)有望成为一种新型、有效的抑制眼部新生血管的药物。我们就ES在抗新生血管性眼病治疗中的研究进展作一综述。  相似文献
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号